Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2

Margarita Malakhova, Valentina Tereshko, Sung-Young Lee, Ke Yao, Yong-Yeon Cho, Ann Bode, Zigang Dong



Supplementary Figure 1. Two perpendicular views of the crystallographic dimer. Crystal packing results in a dimer formation through T-loop residues 569-585, whereas in solution the CTD exists as a monomer (**Supplementary Methods**). In the crystals the dimer is stabilized by the disulfide bond formed between the Cys579 residues (shown as a small spheres) of two symmetry-related molecules.





Supplementary Figure 2. The CTD RSK2 superposition with the selected kinases. (a) The active PKA (chain A, PDB 1CDK). The CTD T-loop residues 579-585 and the adjacent α F-helix residues 586-590 (in gold) are partially disordered in most of the crystals tested, which suggests flexibility of that region in solution and refolding upon phosphorylation. The comparison of CTD and PKA structures suggests that the α L-helix displacement might be associated with the rearrangement of the phosphorylated T-loop and its reposition in the front of the catalytic cleft. (b) The autoinhibited Ca²⁺/calmodulin-dependent kinase CaMKII, PDB 2BDW. (c) MAPK-activated protein kinase 2 (MK2) crystallized in the constitutively active conformation¹³ -MK2-a, PDB ID 1NXK, chain C. (d) MK2 in an inactive conformation¹⁴ - MK2-i, PDB 1KWP. (e) MK2 in the complex with p38α¹⁵ - MK2+p38α, PDB 2OZA.



In active MK2-a (**c**), the autoinhibitory C-terminal α K-helix is displaced from its position underneath the catalytic cleft found in inactive MK2-i (**d**) and in MK2 complexed with p38 α (**e**). In both MK2 structures, inactive (**d**) and complexed with p38 α (**e**), the conserved residue Glu145 is involved in the ionic interactions with Lys353 forming an ionic pair analogous to the CTD Glu500-Lys700. In contrast, in MK2-a structure (**c**) with the autoinhibitory α K-helix extruded from a "cradle" the α D-helix is free to move allowing the Glu145 readjustment toward the ATP binding site.





Type C

Supplementary Figure 3. Enhanced Y707A RSK2 activity in Xenopus embryos. (a) Example of a normal embryo (Type A) after injection with the mRNA of β -galactosidase (1) ng) as a control. Example of phenotype deformity, Type B (b) and Type C (c) induced by injection with mRNA of RSK2 wild type or the Y707A RSK2 at various concentrations. Both embryo types exhibited anterior-posterior axis (A-P axis) defects. (d) Histogram showing the occurrence of Type A, B, and C embryos after injection with various amounts (100 pg-1 ng) of mRNA of the wild type RSK2 or mutant Y707A RSK2. These data are representative of at least three independent experiments. The mutant Y707A RSK2 induced a phenotypic change that was more severe than that induced by wild type RSK2 expression. The injection of wild type RSK2 mRNA at 100 pg did not induce a phenotypic change (lane 1),

whereas injection of an equivalent amount of mutant Y707A RSK2 mRNA resulted in an A-P axis defective phenotype (Type B or C) in most of the embryos (~90%) (lane 2). (e) Western blot analysis demonstrated that approximately similar amounts of the wild type (W) or Y707A mutant (Y) forms of RSK2 are expressed in the embryos when an equivalent amount of RNA (100 pg – 1ng) is introduced.

		β1			β2			β3				αC				β	4		β5		
	420							· 1												4	95
CTD	OFTD	GYEVK-	EDIG	VGSYS	VCKRO	cink/	ATNM	EFAVK	IIDKS	skrdp'-		TEEIH	EILLR	YGO	HPNI	ITL	kdvydi	D	-GKYV	VVT	EL
MK2	ÃIID	DYKVTS	OVLG	GING	KVLOI	FNK	RTOE	(FALK	MLODO]	PKZ	ARREVI	ELHWR	ASÕ	CPHI	VRI	VDVYE	NLYA	GRKCLI	IVM	EC
CaMKT	DTRD	TYDER-	DVLG	GAES	EVTL	EDK	RTOKI	VATK	CTARK	ALEG -	- KEGSN	MENETZ	AVT.HK	т – к і	P NT	VAL		SG	GHLY	ттм	OT.
CaMKIT	KESD	NYDVK-	EELG	KGAFS	VVRRC	WHKT	TTGL	TAAK	TINTE	KLS- Z	RDFOR	LEREAL	RTCRK		PNT	VRL	HDSTO	сс ЕЕ	SEHY	TVF	от.
DKA	FHLD	OFFRI-	KTLC	CSFC	RVMT.	/KHK	T C NI	TEAMK	TLDKC		KOT FH	TLNEKI	RTT.OA	V-NI	FDFT	.VKT.	FVSFK	 	SNLV	MVM	FV
1 IAA	פננוויז	v#	# 1C	10010	77	# F	T	fa K				# P	I I I I I I I I I I I I I I I I I I I	#	Di	ττ I	d 2#	DIN	9	1 37	#
	D	у #	# 19	G .	v	#K	-	TUV	÷			#15	•	#	r 1	· · ·	u .0#		°C	• • • •	π
		0.5	_					_		0.5		0-	_		0	_	0.0				
		BD	αD					αE		<u>р</u> 6		b .	/		þ	8	, ps	,		_	
		500																		5	76
CTD		MK GGE L	LDKI	LRQ-K	-FFSE	EREAS	SAVLE	TITK	TVE Y I	HAQGV	HRDLE	KPSNI	LYVDE	SGNI	PESI	RIC	DFGFA	KQLR	AENGLI	- – M	-
MK2		LD GGE L	FSRI	QDRGD	QAFTE	REAS	SEIMM	KSIGE.	AIQ y i	HSINI	HRDVE	KPENL	LYTSK	RPN	A-II	KLT.	DFGFA	KETT	SHNSLI	TPC	Y
CaMKI		VS GGE L	FDRI	VEK-G	-FYT E	RDAS	SRLIE	FQVLD.	AVKYI	HDLGI	HRDLE	KPENLI	LYYSL	DEDS	SK-I	MIS	DFglsl	kmed	lpgsvls	stac	g
CaMKII		VT GGE L	FFDI	VAR-V	-FYS E	CADAS	SHCIÇ	QQILE	SIAY	CHSNGI	HRNLE	KPENL	LASK	AKGA	AA – V	KLA	DFGLA	I EVN	DSEAWH	IGFA	G
PKA		VP GGEM	FSHL	RRI-G	-RFS	PHA F	RFYAA	AQIVL	TFE Y I	HSLDL	YRDL	KPENLI	LID	QQG	Y 1	QVT:	DFGFA	KRVK	GRT-WI	L-C	G
		! GGEl	f #i		f\$ E	s #As	5	i	# Y 1	H !	hRdl	KPeN11	L%		!	1 1	DFG%a	k	8		
						6	γF						ac	:			αΤ		αJ		
		580			I	C	χF	503	I		I		αΘ	;			αΙ		αJ		659
CITID		580	- NFV		FROG) מהאמת	αF e	503	T. V TMT	TCVT		- יזירורום	αΘ	; 	reck	FQT.			αJ Ι	NGKI	659 M
CTD		580 TP C Y TA	-NFV	APEVL	 ERQGY		XF E CDIWS	503 SL GV L	 L y TMI	TGYT	 PFANGI	PDDT-	αG PEEIL	; ARIC	GSGK	FSL	αI SGGYWI	NSVS	αJ DTA K DI	VSKI	659 M
CTD MK2		580 TP C Y TA TP Y Y VA	-NFV PEVL	A pe vl G pe	 ERQGY K-Y	C CDAAC CDKSC	xF 6 CDIWS CDMWS	503 SL GV L SL GV I	 L Y TMI M Y ILI	TGYT CGYP	 PFANGI PFYSNI	PDDT-1 HGLais	αG PEEIL spgmk	; ARI(tRII	GSGK RMGQ	(FSL)YEF	αI SGGYWI PNPEWI	NSVS SEVS	αJ DTA K DI EEV K MI	IVSKI	659 M L
CTD MK2 CaMKI		580 TP C Y TA TP Y Y VA tP G Y	-NFV. PEVL V.	A pe vl G pe A pe vl	 ERQGY K-Y AQKPY	(DAA) (DAA) (DKS) (SKA)	xF 6 CDIWS CDMWS VDCWS	503 SL GV L SL GV I SI GV I	L Y TMI MYILI AYILI	TGYT CGYP CGYP	 PFANGI PFYSNI PFYDEI	PDDT-1 HGLais NI	α PEEIL spgmk DAKLF	ARIO ARIO TRII EQII	GSGK RMGQ LKAE	YEF YEF	αI SGGYWI PNPEWI DSPYWI	NSVS SEVS DDIS	αJ DTA K DI EEV K MI DSA K DF	VSKI IRNI IRHI	659 M L L
CTD MK2 CaMKI CaMKII		580 TP C Y TA TP Y Y VA tP G Y TP E Y	- NFV. PEVL V. L.	APEVL GPE APEVL SPEVL	 ERQGY K-Y AQKPY KKDPY	C ZDAAC ZDKSC ZSKAN ZSKAN	xF CDIWS CDIWS VDCWS VDCWS VDIWA	503 SLGVL SLGVI SIGVI ACGVI	 L Y TMI M Y ILI A Y ILI L Y ILI	JTGYT JCGYP JCGYP JVGYP	 PFANGI PFYSNI PFYDEI PFWDEI	PDDT-1 HGLai: NI D(αG PEEIL spgmk DAKLF QHRLY	; ARI(tRII EQII AQII	GSGK RMGQ LKAE KAGA	YEF YEF YEF	αI SGGYWI PNPEWI DSPYWI PSPEWI	NSVS SEVS DDIS DTVT	αJ DTAKDI EEVKMI DSAKDF PEAKSI	JVSKI JIRNI JIRHI JIDSI	659 M L L M
CTD MK2 CaMKI CaMKII PKA		580 TP C Y TA TP Y Y VA tP G Y TP E Y TP E Y	- NFV. PEVL V. L.	APEVL GPE APEVL SPEVL APEII	 ERQGY K-Y AQKPY KKDPY LSKGY	CDAAC DAAC DKSC SKAV SKAV SKPV	xF CDIWS CDMWS VDCWS VDIWZ VDIWZ	503 SLGVL SLGVI SIGVI ACGVI ALGVL	 LYTMI MYILI AYILI LYILI IYEM2	JTGYT JCGYP JCGYP JVGYP JVGYP	PFANGI PFYSNI PFYDEI PFWDEI PFFAD(PDDT-1 HGLais N[D(Q]	αG PEEIL spgmk DAKLF QHRLY PIQIY	; ARI(ERII EQII AQII EKIV	GSGK RMGQ LKAE KAGA VSGK	YEF YEF YDY VRF	αI SGGYWI PNPEWI DSPYWI PSPEWI P-PSH	NSVS SEVS DDIS DTVT FS	αJ DTA K DI EEV K MI DSA K DF PEA K SI SDL K I	JVSKI JIRNI JIRHI JIDSI JLRNI	659 M L L M L
CTD MK2 CaMKI CaMKII PKA		580 TPCYTA TPYYVA tPGY TPEY TPEY TP Y	- NFV. PEVL V. L. L.	APEVL GPE APEVL SPEVL APEII PE!!	 ERQGY K-Y AQKPY KKDPY LSKGY # Y	CDAAC CDKSC CSKAV CSKAV CSKAV CNKAV C k	XF CDIWS CDMWS VDCWS VDIWA VDIWA DWWA D W	503 SL GV L SL GV I SI GV I AC GV I AL GV L 1 GV !	 LYTMI MYILI AYILI LYILI IYEMA Y !!	JTGYT JCGYP JCGYP JVGYP JVGYP LAGYP	 PFANGH PFYSNH PFYDEH PFFADQ PF	PDDT-] HGLais NI D(Q]	αG PEEIL spgmk DAKLF QHRLY PIQIY !	; ARI(EQII EQII AQII EKIV #I	SSGK RMGQ LKAE KAGA VSGK S	CFSL OYEF CYEF AYDY CVRF % %	αI SGGYWI PNPEWI DSPYWI PSPEWI P-PSH W	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF PEAKSI SDLKDI K]	JVSKI JIRNI JIRNI JIDSI JIRNI	659 M L L L L !
CTD MK2 CaMKI CaMKII PKA		580 TPCYTA TPYYVA tPGY TPEY TPEY TP Y	- NFV. PEVL V. L. L.	APEVL GPE APEVL SPEVL APEII PE!!	 ERQGY K-Y AQKPY KKDPY LSKGY # Y	ZDAAQ ZDKSQ ZSKAV ZSKPV ZSKPV ZNKAV Z k	XF CDIWS CDIWS VDCWS VDCWS VDIWZ VDIWZ DWWZ	503 SLGVL SLGVI SIGVI ACGVI ALGVL 1GV!	 LYTMI MYILI AYILI LYILI IYEMA Y !!	JTGYT JCGYP JCGYP JCGYP JVGYP JAGYP GYp	 PFANGH PFYSNH PFYDEN PFWDEI PFFAD(PF	PDDT-] HGLai: N[D(Q]	αG PEEIL spgmk DAKLF QHRLY PIQIY !	; ARIC EQII EQII AQII EKIV #I	SSGK RMGQ LKAE KAGA VSGK S	CFSL QYEF CYEF QYDY CVRF % %	αI SGGYW PNPEW DSPYW PSPEW P-PSH w	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF PEAKSI SDLKDI K 1	JVSKI JIRNI JIRNI JIDSI JIRNI	659 M L L M L
CTD MK2 CaMKI CaMKII PKA		580 TPCYTA TPYYVA tPGY TPEY TPEY TP Y	- NFV. PEVL V. L. L. !	APEVL GPE APEVL SPEVL APEII PE!!	 ERQGY K-Y AQKPY KKDPY LSKGY # Y	(DAAC (DKSC) (SKAV (SKPV (NKAV (NKAV (k	XF CDIWS CDMWS VDCWS VDCWS VDIWA VDWWA D W	503 SLGVL SLGVI SIGVI ACGVI ALGVL 1GV!	 L¥TMI M¥ILI A¥ILI L¥ILI I¥EMA ¥ !!	JTGYT JCGYP JCGYP JCGYP JVGYP JAGYP GYp	 PFANGH PFYSNH PFYDEN PFWDEI PFFAD(PF	PDDT-] HGLai: N[D(2]	αG PEEIL spgmk DAKLF QHRLY PIQIY !	; ARIC EQII EQII AQII EKIV #I	SSGK RMGQ LKAE XAGA VSGK 9	YEF YEF YEF YDY VRF % %	αI SGGYW PNPEW DSPYW PSPEW P-PSH w	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF PEAKSI SDLKDI K 1	JVSKI JIRNI JIRNI JIDSI JLRNI	659 M L L M L
CTD MK2 CaMKI CaMKII PKA		580 TPCYTA TPYYVA tPGY TPEY TPEY TP Y	- NFV. PEVL V. L. L. !	APEVL GPE APEVL SPEVL APEII PE!!	 ERQGY K-Y AQKPY KKDPY LSKGY # Y	(DAAC (DKSC) (SKAV (SKPV (NKAV (NKAV (k	XF CDIWS CDMWS VDCWS VDCWS VDIWA VDWWA D W	503 SLGVL SLGVI SIGVI ACGVI ALGVL 1GV!	 NYILI AYILI LYILI IYEMA Y !!	LTGYT LCGYP LCGYP LCGYP VGYP AGYP GYp	 PFANGH PFYSNH PFYDEH PFWDEH PFFAD(PF	PDDT-1 HGLais N(2]	αG PEEIL spgmk DAKLF QHRLY PIQIY ! 700	; ARIC tRII ΈQΙΙ ΆQΙΗ ΈΚΙΥ #Ι αL-	SSGK RMGÇ LKAE XSGK 9 707	YEF YEF YDY VRF % %	αI SGGYWI PNPEWI DSPYWI PSPEWI P-PSH W	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF PEAKSI SDLKDI K]	JVSKI JIRNI JIRNI JIDSI JLRNI	659 M L L M L
CTD MK2 CaMKI CaMKII PKA CTD	(580 TPCYTA TPYYVA tPGY TPEY TPEY TP Y	-NFV. PEVL V. L. ! !	APEVL GPE APEVL SPEVL APEII PE!! AALVL	 ERQGY AQKPY KKDPY LSKGY # Y	(DAAC (DKSC (SKAV (SKAV (SKAV (SKAV (NKAV (k	XF CDIWS CDMWS VDCWS VDIWA VDWWA D W	503 SLGVL SLGVI SIGVI ACGVI ALGVL 1GV! XK	 NYILI AYILI LYILI IYEMA Y !!	GYT CGYP CGYP VGYP AGYP GYp	 PFANGH PFYSNH PFYDEI PFWDEI PFFAD(PF	PDDT-1 HGLais N D(Q] 	αG PEEIL spgmk DAKLF QHRLY PIQIY ! 700 LV K GA	; ARIC EQII EQII EKIV #I αL- 	GSGK RMGQ LKAE XAGA VSGK 9 707 TYSA	CFSL YEF YEF YDY VRF % %	αI SGGYWI PNPEW: DSPFWI PSPEWI P-PSH W 714 NQ	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF PEAKSI SDLKDI K]	JVSKI JIRNI JIRHI JIDSI JLRNI	659 M L L L !
CTD MK2 CaMKI CaMKII PKA	ł	580 TPCYTA TPYYVA tPGY TPEY TPEY TP Y	-NFV. PEVL V. L. ! Q R LT. O R MT	APEVL GPE APEVL SPEVL APEII PE!! AALVL	 ERQGY AQKPY KKDPY LSKGY # Y	(DAAC (DKSC (SKAV) (SKAV (SKAV (SKAV (SKAV (SKAV) (SKAV (SKAV) (SKAV (SKAV) (SKAV) (SKAV (SKAV)	XF 6 CDIWS CDMWS VDCWS VDCWS VDIWA D W D W HPWIX	503 SLGVL SLGVI SIGVI ACGVI ALGVL 1GV! XK J	 NYILI AYILI LYILI IYEMA Y !! LP-QY VP-OT	JTGYT JCGYP JCGYP JVGYP JAGYP GYp (QLNRQI PLHTSF	PFANGH PFYSNH PFYDEN PFWDEH PFFAD(PF PF	PDDT -] HGLai: N [Q] PHI KERWEI	αG PEEIL spgmk DAKLF QHRLY PIQIY ! 700 LV K GA DV K EE	; ARIC EQII AQII EKIV #I αL- MAAT	SSGK RMGQ LKAE VSGK 9 707 FYSA ALAT	CFSL YEF YDY VRF % % LNR	αI SGGYWJ DSPYWJ DSPYWJ PSPEWJ P-PSH W 714 NQ DYGSH	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF PEAKSI SDLKDI K	JVSKI JIRNI JIRNI JIDSI JLRNI	659 M L L M L
CTD MK2 CaMKI CAMKI PKA CTD MK2 CaMKI	(580 TPCYTA TPYYVA tPGY TPEY TPY 560 LHVDPH LKTEPT MEKDPE	-NFV. PEVL V. L. ! QRLT. QRLT. KRFT	APEVL GPE APEVL SPEVL APEII PE!! AALVL ITEFM CEOAL	 =-K-Y AQKPY KKDPY LSKGY # Y	ZDAAC ZDKSC ZSKAX ZSKPY ZNKAX Z k Ri Ni Ni	XF 6 CDIWS CDMWS VDCWS VDCWS VDIWA D W D W HPWIX HPWIX	503 3LGVL 3LGVI 3IGVI 4CGVI 4LGVL 1GV! xK 4 //HWDQ //HWDQ 4QSTK 4QDTA	 MYILI AYILI LYILI YEMA Y !! LP-QY VP-QI LDKNI	TGYT CCYP CCYP VGYP AGYP GYP CQLNRQI PPLHTSF HOSYSE	 PFANGI PFYSNI PFYDEI PFWDEI PFFAD(PF PF	PDDT - 1 HGLai: N[2] PHI KERWEI	αG PEEIL spgmk DAKLF QHRLY PIQIY ! 700 LVKGA DVKEA	ARIC ARIC EQII AQII EKIV #I αL- MAA MTSZ	SSGK RMGC LKAE VSGK 9 707 FYSA ALAT	(FSL (YEF) (YDY (VRF % % (LNR) (MRV)	αI SGGYWJ PNPEWJ DSPYWJ PSPEWJ P-PSH W 714 NQ DYGSH HMRKL	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF PEAKSI SDLKDI K]	JVSKI JIRNI JIRHI JIDSI JLRNI	659 M L L M L
CTD MK2 CaMKI CaMKII PKA CTD MK2 CaMKII CaMKII	ę	580 TPCYTA TPYYVA tPGY TPEY TPY TPY 560 LHVDPH LKTEPT MEKDPE LTVNPK	- NFV. PEVL V. L. ! QRLT. QRMT KRFT KRIT.	APEVL GPE APEVL SPEVL APEII PE!! AALVL ITEFM CEQAL ADOAL	 =-K-¥ AQKPY KKDPY LSKGY # ¥	ZDAAC ZDKSC ZSKAX ZSKPY ZNKAX Z k RH NH QH QH QH	XF CDIWS CDMWS VDCWS VDCWS VDWF DW (HPWI HPWI HPWI VPWI VPWI (VPWI (VPWI (VPWI (VPWI (VPWI (VPWI (VPWI (VPWS (VPVS (VDCWS (503 3LGVL 3LGVI 3IGVI 4CGVI 1GV! 1GV! 1KK 4GDTA 1RER	 MYILI AYILI LYILI IYEMA Y !! LP-QY VP-QT LDKNI VASAI	TGYT CGYP CGYP VGYP AGYP GYp PQLNRQI PQLNRQI HQSVSI HQSVSI	 PFANGI PFYSNI PFYDEN PFWDEI PFFAD(PF VLKEDI EQII DCLU	PDDT - 1 HGLai: N 1 D (2 1 PHI KERWEI KKNFAI KKFNAI	αG PEEIL spgmk DAKLF QHRLY PIQIY ! 700 LVKGA DVKEA KSKWK RRKLK	ARIC ARIC EQII AQII EKIV #I αL- MAA QAFI	SSGK RMGQ LKAE XAGA VSGK 9 707 FYSA ALAT NATA	(FSL)YEF (YDY (VRF % % LNR (MRV) (VVR)	αI SGGYWJ PNPEW DSPYW PSPEW P-PSH W 714 NQ DYGSH HMRKL RNLSN	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF 'PEAKSI SDLKDI K 1	JVSKI JIRNI JIRHI JIDSI JLRNI	659 M L L L !
CTD MK2 CaMKII PKA CTD MK2 CaMKI CaMKII PKA	LOVI	580 TPCYTA TPYYA tPGY TPEY TPEY TP Y 560 LHVDPH LKTEPT MEKDPE LTVNPK	-NFV. PEVL V. L. ! QRLT. QRMT KRFT KRIT.	APEVL GPE APEVL SPEVL PE!! AALVL ITEFM CEQAL ADQAL GVNDI	 ERQGY AQKPY KKDPY LSKGY # Y	(DAAC (DKSC (SKAX (SKPX (NKAX (k RH NH QH KT	XF 6 CDIWS CDMWS VDCWS VDWF D W (HPWIN HPWIN HPWIN VPWIC VPWIC VPWIC	503 SLGVL SLGVI SIGVI ALGVI 1GV! XK JUNDQ VHWDQ VHWDQ VHWDQ VHWDQ VHWDQ XK AGDTA CNRER ALYOP	 NYILI AYILI LYILI IYEMA Y !! LP-QY VP-QI LDKNI VASAI	CGYP CGYP CGYP VGYP AGYP GYP CULNRQI CPLHTSF HQSVSE HRQDT CHRQDT	PFANGI PFYSNI PFYDEI PFWDEI PFFAD(PF PF VLKEDI CCLI (GeGDT)	PDDT - 1 HGLais D(2) PHI KERWEI KKNFAI KKFNAI SNFDD'	αG PEEIL spgmk DAKLF QHRLY PIQIY ! 700 LVKGA DVKEE KSKWK RRKLK YEEE	ARIC LRII EQII AQIH EKIV #I -αL- MAA QAFI GAII	SSGK RMGQ LKAE XAGA VSGK 9 707 FYSA ALAT NATA LTTM	CFSL 2YEF 2YEF 2YEF 2YDY 2VRF 8 % 2LNR 2MRV 2WR 1IAT	αI SGGYWJ PNPEWJ DSPYWJ PSPEWJ PSPEWJ PSPEWJ W 714 NQ DYGSH HMRKL RNLSN	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF PEAKSI SDLKDI K]	JVSKI JIRNI JIRHI JIDSI JLRNI	659 M L L !
CTD MK2 CaMKI PKA CTD MK2 CaMKI CaMKII PKA	LQVI	580 TPCYTA TPYVA tPGY TPEY TPEY TP Y 560 LHVDPH LKTEPT MEKDPE LTVNPK DLTKRFG 1 #p	-NFV. PEVL V. L QRLT. QRLT. QRMT KRFT KRFT. NLKD #R +	APEVL GPE APEVL SPEVL APEII PE!! AALVL ITEFM CEQAL ADQAL GVNDI	 ERQG3 AQKP3 KKDP3 LSKG3 # 3	(DAAC (DKSC) (SKAX (SKPX (NKAX (NKAX (K K RH RH PH K (FAT) #1	XF C CDIWS CDMWS VDCWS VDIWA VDWWA D W HPWIA VPWIC IDWIA DOWIA	503 SLGVL SLGVI SIGVI ACGVI ALGV! 1GV! XK UHWDQ VHWDQ VHWDQ VHWDQ VHWDQ XK AGDTA CNRER AIYQR	 HYTMI MYILI LYILI IYEMA Y !! LP-QY VP-QI LDKNI VASAI KVEAF	JTGYT JCGYP JCGYP LGYP LAGYP GYP JUST JUS	PFANGI PFYSNI PFYDEI PFWDEI PFFAD(PF PF PF PF PF PF PF PF QAQII CDCLI (GPGDT)	PDDT - I HGLai: N(Q(Q) KERWEI KKNFAI KKFNAI SNFDD	αG PEEIL spgmk DAKLF QHRLY PIQIY ! 700 LVKGA DVKEE KSKWK RRKLK YEEEE k	ARIC ARIC EQII EQII EKIV #I αL- MAA QAFI GAII	SSGK RMGC LKAE XAGA VSGK 9 707 TYSA ALAT NATA LTTM	CFSL 2YEF 2YEF 2YDY CVRF % % LNR MRV WVR	αI SGGYW PNPEW DSPYW PSPEW P-PSH W 714 NQ DYGSH HMRKL RNLSN	NSVS SEVS DDIS DTVT FS	αJ DTAKDI EEVKMI DSAKDF PEAKSI SDLKDI K]	JVSKI JIRNI JIDSI JLRNI	659 M L L M L



Supplementary Figure 4. Sequence alignment based on the secondary structure determined by X-ray crystallography. Secondary structure elements of aligned sequences are numbered and are highlighted with colors that match those in the folding diagram of **Fig.1a**. The CTD residue numbering (with each 10th residue shown with a vertical line) is below the secondary structure diagram. Amino acids conserved in five kinases are shown in bold. Insertions/deletions in kinase sequences are shown as dashed lines. The residues that are disordered in the crystal structures are shown in lower case letters. The CTD RSK2 N-terminal residues 399-410 and C-terminal residues 715-440, which are disordered in the crystal structure, are omitted from the alignment.

	Se-Met	Native
	derivative	
Data collection		
Space group	P4 ₁ 2 ₁ 2	P4 ₁ 2 ₁ 2
Cell dimensions		
<i>a</i> , <i>b</i> , <i>c</i> (Å)	46.59, 46.59, 293.99	46.91, 46.91, 291.08
α, β, γ (°)	90, 90, 90	90, 90, 90
Resolution ^{b)} (Å)	50-2.0 (2.06-2.0)	50-2.0 (2.06-2.0)
R _{merge}	0.079 (0.44)	0.08 (0.47)
Ι/σΙ	36.9 (6.0)	30.6 (3.0)
Completeness (%)	99.9 (100)	98.8 (99.0)
Redundancy	7.7 (7.1)	5.5 (5.3)
Refinement		
Resolution (Å)	20 - 2.0	20 - 2.0
No. reflections	23160	23175
$R_{ m work}/R_{ m free}$	0.202 / 0.237	0.217 / 0.256
No. atoms		
Protein	2340	2361
Ions	1 Na	1 Na
Water	91	77
B-factors		
Protein	44.9	53.0
Ions	42.3	48.4
Water	46.8	54.3
R.m.s deviations		
Bond lengths (Å)	0.012	0.013
Bond angles (°)	1.21	1.23

Supplementary Table 1. X-ray data collection and refinement statistics^{a)}

^{a)} One SeMet labeled and one native crystal was used for the structure determination. ^{b)} Highest resolution shell is shown in parenthesis.

Materials and Methods

Protein purification and crystallization. The CTD of murine RSK2 (residues 399-740) was subcloned into the pET-46 EK/LIC vector (EMD Chemicals, Inc., Can Diego, CA) and expressed in E.coli BL21-Codon Plus (DE3)-RILP (Stratagene, La Jolla, CA) competent cells. Soluble His-tagged CTD RSK2 was purified on nickel-nitriloacetic acid agarose (Qiagen, Valencia, CA), and treated with enterokinase to remove the His-tag. Untagged protein was eluted as a monomer on a HiLoad 16/60 Superdex-200 size-exclusion chromatography column (GE Healthcare, Piscataway, NJ). Selenomethionine-labeled protein (SeMet) was obtained by standard procedures¹. Several crystallization conditions were determined with Index crystallization screening (Hampton Research, Aliso Viego, CA) and optimized. The protein samples (5-13 mg/ml in the presence of 10 mM β -mercaptoethanol) were mixed with an equal volume of precipitant that contained 7.5%-10% polyethylene glycol 3350, 50 mM ammonium sulfate, and 0.1 M Hepes (pH 7.0). Crystal soaking and co-crystallization trials in the presence of the non-hydrolyzable ATP analogue, AMP-PNP and MgCl₂ were performed using a broad range of incubation and co-crystallization conditions. All obtained crystals were cryo-protected in mother liquor with 20% ethylene glycol and flash-frozen in liquid nitrogen.

Data collection and structure determination. The SeMet labeled and native CTD RSK2 crystals were isomorphous and belonged to the P4₁2₁2 space group. Single-wavelength anomalous dispersion (SeMet labeled protein, Se-edge energy, λ =0.97936 Å) and native (λ =0.97950 Å) X-ray data sets were collected at 100K at Advanced Photon Source (Argonne National Laboratory) using the 23ID-D and 24ID-C beam lines, respectively. Both X-ray data

sets were collected using 280 mm crystal-to-detector distance, 0.5° oscillation width and 2 sec exposure time. Images were processed and scaled with HKL2000².

The structure was solved by SAD technique on SeMet labeled crystals. A heavy atom search was performed in SHELXD³ using X-ray data collected at peak energy and 3.5 Å resolution cut-off. SAD phasing and density modification were performed with the use of the SOLVE/RESOLVE suite⁴. The model building performed with the RESOLVE basic script was completed using the ARP/wARP program⁵. The electron density and model examinations were performed using TURBO-FRODO⁶. The restrained positional and isotropic B-factor refinement was done in REFMAC5⁷. R-free was monitored by setting aside 5% of the reflection as a test set. Crystal data, X-ray data collection and refinement statistics are listed in Table 1. A Ramachandran plot calculated with PROCHECK⁸ indicated that 93.1% and 6.9% of the non-Gly and non-Pro residues in the final models lie in the most favored and additional allowed regions, respectively. The surface area calculations were performed using Protein-Protein Interaction Server (http://www.biochem.ucl.ac.uk/bsm/PP/server). The three-dimensional figures were prepared with the use of RIBBONS⁹. The potential surface was prepared with GRASP¹⁰. All numbering of amino acid residues is according to full length murine RSK2.

Xenopus experiments. Mouse RSK2 full length or the Y707A mutant plasmid was inserted into a BglII/XbaI digested pCS2-flag tagged vector. mRNA synthesis and microinjection were performed as previously described^{11,12}. Fertilized eggs were injected in the animal pole with messenger RNA at the one-cell stage. The embryos were then cultured for 3 or 4 day in 30% Modified Frog Ringers (MR) buffer comprised of 0.1 M NaCl, 2 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, 5 mM HEPES, pH 7.6. The embryos, which were cultured until stage 40, were rinsed several times with 1X PBS, fixed for one hour at room temperature in MEMFA (0.1 M MOPS, 2 mM EGTA, 1 mM MgSO₄, 3.7% formaldehyde), and stored at 4°C in 100% methanol. Fixed embryos were observed and photographed under a microscope. An anti-Flag antibody (Sigma-Aldrich, St. Louis, MO) was used for the detection of the equivalent expression of RSK2 by Western blot analysis. Detection of α -tubulin was used as a loading control.

Supplementary References

- Doublie, S. Preparation of Selenomethionyl Proteins for Phase Determination. *Methods* in Enzymology 276, 523-530 (1977).
- Otwinowski, Z., Minor, W. Processing of x-ray diffraction data collected in oscillation mode. *Methods in Enzymology* 276, 307-326 (1997).
- Schneider, T.R., Sheldrick, G.M. Substructure solution with SHELXD. Acta Crystallogr. D Biol. Crystallogr. 58, 1772-1779 (2002).
- 4. Terwilliger, T.C., Berendzen, J. Automated MAD and MIR structure solution. *Acta Crystallogr.*, *D Biol. Crystallogr.* **55**, 849-861 (1999).
- Lamzin, V.S., Perrakis, A., Wilson, K.S. *The ARP/WARP suite for automated construction and refinement of protein models. In Int. Tables for Crystallography*, 720-722 (Dordrecht, Kluwer Academic Publishers, The Netherlands, 2001).
- Cambillau, C., Roussel, A. Turbo Frodo, version OpenGL.1. in University Aix-Marseille II: marseille (1997).
- Murshudov, G.N., Vagin, A.A., Dodson, E.J. Refinement of macromolecular structures by maximum-likelihood method. *Acta Crystallogr.*, *D Biol. Crystallogr.* 53, 240-255 (1997).

- 8. Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M. PROCHECK: a program to check the stereochemical quality of protein structures. *J. Appl. Cryst.* **26**, 283-291 (1993).
- 9. Carson, M. Ribbons. *Methods in Enzymology* **277**, 493-505 (1996).
- 10. Nicholls, A., Sharp, K.A., Honig, B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. *Proteins* **11**, 281-296 (1991).
- Dong, Z. *et al.* AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin. *J. Biol. Chem.* 271, 9942-9946.
- 12. Xu, R. H. *et al.* Involvement of Ras/Raf/AP-1 in BMP-4 signaling during Xenopus embryonic development. *Proc. Natl. Acad. Sci. USA* **93**, 834-838 (1996).
- 13. Underwood, K.W. *et al.* Catalytically active MAP KAP kinase 2 structures in complex with starosporine and ADP reveal differences with the autoinhibited enzyme. *Structure* 11, 627-636 (2003).
- Meng, W. *et al.* Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export. *J.Biol.Chem.* 277, 37401-37405 (2002).
- 15. White, A., Pargellis, C.A., Studts, J.M., Werneburg, B.G., Farmer II, B.T. Molecular basis of MAPK-activated protein kinase 2:p38 assembly. *PNAS* **104**, 6353-6358 (2007).